JAK3 Staining and CD68+ Macrophage Counts are Increased in Patients with IgA Nephropathy
Authors:
- Mateus Justi LuvizottoMLMateus Justi Luvizotto
- Precil Diego Miranda de Menezes NevesPNPrecil Diego Miranda de Menezes Neves
- Cristiane Bitencourt DiasCDCristiane Bitencourt Dias
- Lecticia Barbosa JorgeLJLecticia Barbosa Jorge
- Luis YuLuis Yu
- Luísa Menezes-SilvaLMLuísa Menezes-Silva
- Magaiver Andrade-SilvaMAMagaiver Andrade-Silva
- Renato C. MonteiroRMRenato C. Monteiro
- Niels Olsen Saraiva CâmaraNCNiels Olsen Saraiva Câmara
- Viktoria WoronikVWViktoria Woronik
Preprint
- 1 January 2026
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Background/Objectives: IgA nephropathy (IgAN) is the most common primary glomerulopathy worldwide; it is characterized by a complex pathophysiology involving several inflammatory pathways. The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway may be critical in this process. This study aimed to investigate the role of this pathway in IgAN and examine related tissue inflammatory markers. Methods: We analyzed 63 biopsy-confirmed patients with IgAN and performed immunohistochemical analysis on renal samples. A panel of antibodies targeting the JAK/STAT pathway, including JAK2, JAK3, p-STAT, STAT3, and MAPK/ERK, was used for this analysis. Six kidney tumor border samples were used as controls. Additionally, CD68 staining was used to evaluate tissue inflammation in the kidney biopsies. Results: Patients with IgAN showed a significantly higher cellular density of JAK3 staining at the glomerular level compared to controls, indicating JAK3 activation (p < 0.0002). Nevertheless, the correlation between JAK3 positivity in glomeruli and clinical parameters such as the initial and final estimated glomerular filtration rate (eGFR) and proteinuria was not statistically significant. Identical results were obtained with CD68+ macrophage counts in the glomerular compartment, which did not show any correlation with clinical parameters, while CD68+ tubulointerstitial staining demonstrated a significant correlation with both initial (p = 0.002) and final eGFRs (p = 0.0014), proteinuria (p = 0.010), and interstitial fibrosis (p < 0.001), as well as with renal disease progression (p = 0.005). Conclusions: Patients with IgAN exhibited activation of the JAK/STAT pathway, in contrast to controls. Macrophage CD68 staining in the tubulointerstitial area increased and was associated with clinical and laboratory parameters such as eGFR and proteinuria. Additionally, MEST-C histological parameters, such as segmental glomerulosclerosis (S0/S1), tubular atrophy/interstitial fibrosis (T0/T1/T2), and crescents (C0/C1/C2), were associated with a higher number of CD68+ cells.Keywords
All Related Versions
- Version 1, 2026-01-01, Preprints
- Published version: Diagnostics, 16 (3), 437.
This publication has 26 references indexed in Scilit:
- LIF/JAK2/STAT1 Signaling Enhances Production of Galactose-Deficient IgA1 by IgA1-Producing Cell Lines Derived From Tonsils of Patients With IgA NephropathyKidney International Reports, 2023
- Treatment strategy with multidrug therapy and tonsillectomy pulse therapy for childhood-onset severe IgA nephropathyClinical and Experimental Nephrology, 2022
- Oxidative stress and macrophage infiltration in IgA nephropathyJournal Of Nephrology, 2021
- The role of JAK/STAT signaling pathway and its inhibitors in diseasesInternational Immunopharmacology, 2020
- M2a and M2b macrophages predominate in kidney tissues and M2 subpopulations were associated with the severity of disease of IgAN patientsClinical Immunology, 2019
- Inhibition of STAT3 Signaling Reduces IgA1 Autoantigen Production in IgA NephropathyKidney International Reports, 2017
- Podocyte-specific JAK2 overexpression worsens diabetic kidney disease in miceKidney International, 2017
- Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working GroupKidney International, 2017
- JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future ProspectsDrugs, 2017
- JAK inhibition in the treatment of diabetic kidney diseaseDiabetologia, 2016